The Trump administration on Dec. 10 denied allegations that its study on the safety of an abortion pill has been slowed down.
Bloomberg News had reported this week, citing anonymous sources, that Food and Drug Administration Commissioner Dr. Marty Makary recently directed regulators to delay the study of mifepristone until after the 2026 midterm elections.
“The study is not being ‘slow walked,’” a White House official told The Epoch Times. “Comprehensive and exhaustive reviews take time.”
The FDA started the review earlier this year, following orders from Health Secretary Robert F. Kennedy Jr. and an analysis of insurance claims that found that about one in 10 women who took mifepristone experienced serious adverse events. The review is “progressing and ongoing,” Kennedy told senators in the fall, citing Makary….